ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 during the Class Period from February 2, 2024, to October 22, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of Alto's common stock during the IPO and the specified Class Period [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by September 19, 2025, to represent other class members [3]. Group 2: Allegations Against Alto Neuroscience - Defendants allegedly made false statements about ALTO-100's effectiveness in treating major depressive disorder, overstating its clinical and commercial prospects [5]. - The lawsuit claims that Alto's business and financial prospects were also overstated due to these misleading statements [5]. - Investors reportedly suffered damages when the true details about the product and the company's prospects became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements and has a history of successful outcomes for its clients [4].